Merrimack Pharmaceuticals, Inc. (MP6N.F)
| Previous close | 3.8200 |
| Open | 3.8200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.8200 - 3.8200 |
| 52-week range | 3.0400 - 7.0500 |
| Volume | |
| Avg. volume | 25 |
| Market cap | 53.027M |
| Beta (5Y monthly) | 1.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1340 |
| Earnings date | 07 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
CAMBRIDGE, Mass., April 30, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced that it has filed notice with NASDAQ of the Company’s intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024. Under the Plan of Dissolution, Merrimack intends to issue an initial liquidating cash dividend to its sto
Business WireMerrimack Receives $225 Million Milestone Payment from Ipsen
CAMBRIDGE, Mass., March 27, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
Business WireMerrimack Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 07, 2024--Merrimack Reports Full Year 2023 Financial Results
